ABUS RNAi Play

• Einstellung aller Coronavirus- und oralen RNA-Destabilisierungsprogramme, einschließlich AB-343 und AB-161
  
• Cashreichweite bis Q3/25
  

https://investor.arbutusbio.com/news-releases/...dosing-first-subject

 

Zahlen für Q2/23

• Umsatz 5 Mio. $
  
• Verlust 17 Mio. $
  
• Cash 152 Mio. $
  
• MK 288 Mio. $
  

https://investor.arbutusbio.com/news-releases/...inancial-results-and

 

https://investor.arbutusbio.com/node/18261/pdf

Interessant auch die Hinweise zu den Klagen gg. Moderna und Biontech/Pfizer:

The above corporate updates do not affect the Company’s pending litigations. Arbutus will continue to protect and defend its intellectual property,
which is the subject of the on-going lawsuits against Moderna and Pfizer/BioNTech. The Company is seeking fair compensation for Moderna’s and
Pfizer/BioNTech’s use of its patented LNP technology that was developed with great effort and at a great expense, without which Moderna and
Pfizer/BioNTech’s COVID-19 vaccines would not have been successful. Document production is currently on-going in the lawsuit against Moderna
with the claim construction hearing scheduled for February 7, 2024. Document and written discovery in the lawsuit against Pfizer/BioNTech is ongoing
and a date for a claim construction hearing has not been set  

Zahlen für Q3/23

• Umsatz 5 Mio. $
  
• Verlust 20 Mio. $
  
• Cash 145 Mio. $
  
• MK 307 Mio. $
  

-Reducing workforce by 24% as a result of recent pipeline optimization

- Cash runway extended into first quarter 2026

https://investor.arbutusbio.com/news-releases/...inancial-results-and